Literature DB >> 33375030

Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy.

Veerle Ide1, Dirk Vanderschueren1,2, Leen Antonio1,2.   

Abstract

Central hypogonadism is a clinical condition, characterized by sexual symptoms and low serum testosterone levels, due to an impaired function of the hypothalamus or pituitary gland. Testosterone replacement therapy (TRT) is the standard treatment for hypogonadism, but it has some disadvantages. TRT is not a good option in men wishing to preserve fertility, nor in men with (a high risk of) prostate cancer, polycythemia, thrombophilia and severe cardiovascular disease. In this review, we discuss alternative treatments for central hypogonadism. If reversible causes are present, non-pharmacological interventions can be therapeutic. Gonadotropins are a good alternative to TRT when fertility is desired in the near future though they require frequent injections. Clomiphene citrate and tamoxifen seem to be a safe alternative for the treatment of functional central hypogonadism in men, as several studies reported a significant increase in testosterone levels with these drugs. However, their use is off-label and data supporting the efficacy of clomiphene citrate and tamoxifen on hypogonadal symptoms are insufficient. For this reason, clomiphene citrate and tamoxifen should not be used in routine clinical practice to treat sexual symptoms in men with central hypogonadism.

Entities:  

Keywords:  aromatase inhibitors; central hypogonadism; clomiphene citrate; functional hypogonadism; gonadotropins; hypogonadotropic hypogonadism; late-onset hypogonadism; tamoxifen

Year:  2020        PMID: 33375030     DOI: 10.3390/ijms22010021

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  5 in total

1.  Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles.

Authors:  Natalia Leciejewska; Paweł A Kołodziejski; Maciej Sassek; Leszek Nogowski; Emilian Małek; Ewa Pruszyńska-Oszmałek
Journal:  Int J Mol Sci       Date:  2022-04-15       Impact factor: 6.208

2.  The role of clomiphene citrate in late onset male hypogonadism.

Authors:  Carlos Teodósio Da Ros; Lucas Uglione Da Ros; João Pedro Uglione Da Ros
Journal:  Int Braz J Urol       Date:  2022 Sep-Oct       Impact factor: 3.050

Review 3.  The Effects of Tamoxifen on Tolerogenic Cells in Cancer.

Authors:  Ros Akmal Mohd Idris; Ali Mussa; Suhana Ahmad; Mohammad A I Al-Hatamleh; Rosline Hassan; Tengku Ahmad Damitri Al Astani Tengku Din; Wan Faiziah Wan Abdul Rahman; Norhafiza Mat Lazim; Jennifer C Boer; Magdalena Plebanski; Rohimah Mohamud
Journal:  Biology (Basel)       Date:  2022-08-17

4.  Kyzatrex - Oral testosterone replacement therapy.

Authors:  Adam Ali Asghar; Mahnoor Rehan Hashmi; Rushaan Ahmed; Yumna Khabir
Journal:  Ann Med Surg (Lond)       Date:  2022-09-11

5.  Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.

Authors:  Filippo Ceccato; Laura Lizzul; Giacomo Voltan; Mattia Barbot; Carla Scaroni
Journal:  Pituitary       Date:  2021-06-26       Impact factor: 4.107

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.